How reliable is the high-volume definition in prostate cancer patients: the potential game-changing role of PSMA

Basit Öğe Kaydı
dc.contributor.authorGuven, Osman
dc.contributor.authorKaryagar, Savas
dc.contributor.authorArici, Serdar
dc.contributor.authorOzulker, Tamer
dc.contributor.authorCan, Orcun
dc.date.accessioned2024-05-20T15:38:43Z
dc.date.available2024-05-20T15:38:43Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractPurposeTo evaluate whether metabolic and volumetric data from Ga-68-PSMA PET/CT performed during staging of de-novo high-volume mCSPC patients who received docetaxel could be used to predict survival. MethodsForty-two de-novo high-volume mCSPC patients, who received ADT + Docetaxel and underwent Ga-68-PSMA PET/CT for staging, were included in the study. The association between patients' pathological data, all PSA measurements, treatments they received, the data obtained from Ga-68-PSMA PET/CT and progression-free and overall survival were examined. ResultsIn the multivariate analysis, PSMA-TV (primary) and PSMA-TV (WB) variables were shown to be independent negative predictors of overall survival. For the threshold value of 19.91 cm(3) obtained for PSMA-TV (primary), HR was calculated as 6.31, the 95% confidence interval (CI): 1.01-39.18, P = 0.048. For the threshold value of 1226.5 cm(3) obtained for PSMA-TV (WB) variable, HR was calculated as 58.62, the 95% CI: 2.55-1344.43, P = 0.011. In our study, SUVmax (WB) variable was found to be an independent and negative predictor of progression-free survival. For the determined threshold value of 17.74, HR was calculated as 16.24, 95% CI: 1.18-22.76, P = 0.037. ConclusionMetabolic and volumetric data obtained from Ga-68-PSMA PET/CT can be used to predict survival in de-novo high-volume mCSPC. Our results show that in ADT + Docetaxel receiving patients, a subgroup with higher PSMA-TV (WB) values have a significantly worse prognosis. This situation suggests that the high-volume disease definition in the literature may be insufficient for this group, and that Ga-68-PSMA PET/CT can play an essential role in demonstrating the heterogeneity within the group.en_US
dc.identifier.doi10.1097/MNM.0000000000001722
dc.identifier.endpage824en_US
dc.identifier.issn0143-3636
dc.identifier.issn1473-5628
dc.identifier.issue9en_US
dc.identifier.pmid37334538en_US
dc.identifier.scopus2-s2.0-85167480492en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage816en_US
dc.identifier.urihttps://doi.org10.1097/MNM.0000000000001722
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4581
dc.identifier.volume44en_US
dc.identifier.wosWOS:001044639500009en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofNuclear Medicine Communicationsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectGa-Psmaen_US
dc.subjectCancer Of Prostateen_US
dc.subjectPet-Cten_US
dc.subjectTumor Volumeen_US
dc.titleHow reliable is the high-volume definition in prostate cancer patients: the potential game-changing role of PSMAen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu